642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological II
Cristina Bagacean, Rémi Letestu, Chadi Al Nawakil, et al.
See abstract for more info.
Gilad Itchaki, Lior Rokach, Ohad Benjamini, et al.
See abstract for more info.
Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, et al.
The ibrutinib regimen is able to extend the PFS compared to the BR in older patients with treatment-naive CLL. The authors of the study support ibrutinib initial therapy for CLL with their data and support the justification for ibrutinib in high-risk diseases. See abstract for more info.
Matthew S. Davids, Danielle M. Brander, Svitlana Tyekucheva, et al.
During a median follow-up of 40.3 months, most patients treated with iFCR continued to have a deep response. This also affected patients with non-mutated IGHV. The safety profile is consistent with the individual toxicities of ibrutinib and FCR. The few relapses have all responded to re-treatment with ibrutinib.
Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, et al.
Peter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Ibrutinib plus rituximab resulted in a superior PFS compared to FCR with no difference in OS.